Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
It is indicate that the expression level of retinoid X receptor (RXR) that is a ligand dependent nuclear receptor is increased by progression of polycystic kidney disease (PKD), RXR localize in nuclei of cystic epithelial cells, and there are a few kind of phosphorylated RXR in nucleus. RXR ligand and phosphatase inhibitor of RXR suppressed progression of PKD. Combination use of its reagents efficiently ameliorates pathological condition of PKD. These results suggest that RXR might be a new target molecule to create therapeutic agent for PKD.
|